135 related articles for article (PubMed ID: 7868749)
1. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi.
Saenz-Santamaría MC; Reed JA; McNutt NS; Shea CR
J Cutan Pathol; 1994 Oct; 21(5):393-7. PubMed ID: 7868749
[TBL] [Abstract][Full Text] [Related]
2. p53 expression is rare in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
[TBL] [Abstract][Full Text] [Related]
3. Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma.
Collins KA; White WL
Am J Dermatopathol; 1995 Oct; 17(5):429-38. PubMed ID: 8599446
[TBL] [Abstract][Full Text] [Related]
4. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 expression in human melanocytes and melanocytic tumors.
van den Oord JJ; Vandeghinste N; De Ley M; De Wolf-Peeters C
Am J Pathol; 1994 Aug; 145(2):294-300. PubMed ID: 8053490
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
8. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma.
Leiter U; Schmid RM; Kaskel P; Peter RU; Krähn G
Arch Dermatol Res; 2000 May; 292(5):225-32. PubMed ID: 10867810
[TBL] [Abstract][Full Text] [Related]
9. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma.
Lohmann CM; Iversen K; Jungbluth AA; Berwick M; Busam KJ
Am J Surg Pathol; 2002 Oct; 26(10):1351-7. PubMed ID: 12360050
[TBL] [Abstract][Full Text] [Related]
10. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi.
Cerroni L; Soyer HP; Kerl H
Am J Dermatopathol; 1995 Feb; 17(1):7-11. PubMed ID: 7695015
[TBL] [Abstract][Full Text] [Related]
11. Increased tenascin expression in melanocytic tumors.
Tuominen H; Kallioinen M
J Cutan Pathol; 1994 Oct; 21(5):424-9. PubMed ID: 7532653
[TBL] [Abstract][Full Text] [Related]
12. Growth dynamics of acquired melanocytic nevi. Higher reactivity of proliferating cell nuclear antigen in junctional and compound nevi than intradermal nevi.
Tokuda Y; Saida T; Mukai K; Takasaki Y
J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):220-4. PubMed ID: 7913717
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanoma with paradoxical maturation.
Ruhoy SM; Prieto VG; Eliason SL; Grichnik JM; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Dec; 24(12):1600-14. PubMed ID: 11117780
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Shea CR
Br J Dermatol; 1995 Dec; 133(6):890-5. PubMed ID: 8547040
[TBL] [Abstract][Full Text] [Related]
15. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-associated expression of transforming growth factor-beta isoforms.
Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
19. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
20. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
